Boston Scientific Corporation $BSX Stock Position Raised by IFM Investors Pty Ltd

IFM Investors Pty Ltd lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 310,126 shares of the medical equipment provider’s stock after purchasing an additional 6,109 shares during the period. IFM Investors Pty Ltd’s holdings in Boston Scientific were worth $30,448,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the period. State Street Corp lifted its stake in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its stake in shares of Boston Scientific by 75.3% during the 2nd quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock worth $17,685,000 after acquiring an additional 70,753 shares in the last quarter. MRA Advisory Group bought a new position in shares of Boston Scientific in the second quarter valued at approximately $273,000. Finally, Bank of New Hampshire grew its holdings in Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after buying an additional 16,699 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a report on Friday, October 17th. Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Royal Bank Of Canada boosted their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $124.85.

Boston Scientific Trading Down 0.4%

Shares of Boston Scientific stock opened at $96.05 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $142.38 billion, a price-to-earnings ratio of 51.36, a PEG ratio of 1.94 and a beta of 0.67. The firm’s 50-day moving average price is $98.67 and its two-hundred day moving average price is $101.17. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 143,095 shares of company stock valued at $14,228,950. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.